tradingkey.logo

Insulet Corp

PODD
View Detailed Chart
289.620USD
-3.260-1.11%
Close 12/19, 16:00ETQuotes delayed by 15 min
20.37BMarket Cap
82.66P/E TTM

Insulet Corp

289.620
-3.260-1.11%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.11%

5 Days

-2.06%

1 Month

-16.38%

6 Months

-4.03%

Year to Date

+10.94%

1 Year

+12.89%

View Detailed Chart

TradingKey Stock Score of Insulet Corp

Currency: USD Updated: 2025-12-19

Key Insights

Insulet Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 42/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 378.05.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Insulet Corp's Score

Industry at a Glance

Industry Ranking
42 / 208
Overall Ranking
120 / 4582
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 27 analysts
Buy
Current Rating
378.047
Target Price
+27.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Insulet Corp Highlights

StrengthsRisks
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.71% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.07B.
Fairly Valued
The company’s latest PE is 82.66, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 72.07M shares, decreasing 4.83% quarter-over-quarter.
Held by Mairs and Power
Star Investor Mairs and Power holds 1.13K shares of this stock.

Insulet Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Insulet Corp Info

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Ticker SymbolPODD
CompanyInsulet Corp
CEOMcevoy (Ashley)
Websitehttps://www.omnipod.com

FAQs

What is the current price of Insulet Corp (PODD)?

The current price of Insulet Corp (PODD) is 289.620.

What is the symbol of Insulet Corp?

The ticker symbol of Insulet Corp is PODD.

What is the 52-week high of Insulet Corp?

The 52-week high of Insulet Corp is 354.880.

What is the 52-week low of Insulet Corp?

The 52-week low of Insulet Corp is 230.050.

What is the market capitalization of Insulet Corp?

The market capitalization of Insulet Corp is 20.37B.

What is the net income of Insulet Corp?

The net income of Insulet Corp is 418.30M.

Is Insulet Corp (PODD) currently rated as Buy, Hold, or Sell?

According to analysts, Insulet Corp (PODD) has an overall rating of Buy, with a price target of 378.047.

What is the Earnings Per Share (EPS TTM) of Insulet Corp (PODD)?

The Earnings Per Share (EPS TTM) of Insulet Corp (PODD) is 3.504.
KeyAI